Pherecydes Pharma strengthens its intellectual property with the first patent granted in Israel for its anti-Staphylococcus aureus phages and provides an update on the development schedule of this phage family

NANTES, France, November 29, 2021– (BUSINESS WIRE) – Regulatory news:

Pharma Pherecides (Paris: ALPHE) (FR0011651694 – ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and / or complicated bacterial infections, today announces that the Israel Patent Office has approved the granting of ‘a patent for its anti-Staphylococcus aureus phages and provides an update on the development schedule for these phages.

The patent obtained in Israel is the first patent granted for this family of phages and provides protection until the end of 2038.

The Staphylococcus aureus program, a bacterium considered a high global priority by the WHO1, is the Company’s flagship program. It includes, at this stage, three clinical trials which should start in the coming months: PhagoDAIR of which Pherecydes Pharma is the sponsor as well as PhagOS and PhagoPied which are funded by the Hospital Clinical Research Programs (PHRC) and whose sponsors will be the University Bordeaux and Nîmes Hospital Centers. At the same time, Pherecydes Pharma plans to make these phages available as part of early access programs to AAC. The AAC and PhagoDAIR applications are currently under review and the Company expects to receive responses by early 2022 and the first quarter of 2022 respectively. The start of the PhagoDAIR study is therefore expected during the first quarter of 2022 and that of the PhagOS and PhagoPied studies before the end of the first half of 2022.

Guy-Charles Fanneau de La Horie, Chairman of the Management Board of Pherecydes Pharma, noted: “We are very happy to continue to strengthen our intellectual property. Following patents issued in many jurisdictions for our anti-Pseudomonas aeruginosa and anti-Escherichia coli phages, this first patent for our anti-Staphylococcus aureus phages further enhance our arsenal of protection covering phages that we are currently developing. This approach is part of our continued efforts to protect our investments in our winning phages and the aggressive stance we have taken in the promising therapeutic area of ​​precision phage therapy. This first step reaffirms the intellectual property strategy implemented by the Company in recent years and will support the development of these assets in the coming months. All this is also taking place in an environment where the demand for compassionate treatment remains strong with 38 patients treated on November 15, 2021 (including 24 patients infected with Staphylococcus aureus), i.e. 15 new patients treated in the first eleven months of 2021.“.

Pherecydes Pharma has an active portfolio of four patents, each covering several phages and their variants against target bacteria: Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. While some patents are still pending, others have already been granted in major jurisdictions such as the United States, Europe, Japan, Australia, Hong Kong and Israel.

For more details on this news, launch the video by clicking on the image below:

About Pherecydes Pharma

Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone represent more than two thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of precision phage therapy has been successfully applied to several dozen patients in the context of compassionate use, under the control of the National Medicines Safety Agency (ANSM). Based in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, the biotechnology sector and academic research.

For more information,


This press release contains non-factual elements including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current vision and assumptions of the management of the Company. They incorporate known and unknown risks and uncertainties that could lead to significant differences in results, profitability and expected events. In addition, Pherecydes Pharma, its shareholders and its affiliates, directors, officers, advisers and employees have not verified the accuracy and make no representations or warranties regarding the statistical information or forward-looking information contained in this press release and which originate or are derived from third party sources or industry publications; these statistical data and forecast information are used in this press release for informational purposes only. Finally, this press release may be written in French and in English. In the event of discrepancies between the two texts, the French version will prevail.

See the source version on


Pherecides Pharma
Philippe Rousseau
[email protected]

Dusan Oresansky
Investor Relations
[email protected]
T.: +33 1 44 71 94 92

Arthur Rusty
Media relations
[email protected]
T.: +33 1 44 71 00 15

Source link

Comments are closed.